NTLA:NASDAQ
Intellia Therapeutics Inc
12,20 $
arrow_downward
−5,35%(−0,69) 1D
12,28 $
arrow_upward
+0,68% (+0,083)bedtimePo zaprtju
Zaprto: 10. jun., 16:00:00 GMT -4 · USD
search
Vsi simboli
1D
5D
1M
6M
TLDD
1L
5L
MAKS
| Simbol | Cena | Sprememba | Odstotna sprememba |
|---|
insights_autoGeneriranje najpomembnejših vpogledov za NTLA …
Odpri
12,66 $
Visoka
13,14 $
Nizka
12,19 $
Tržna kapitalizacija
1,70 mrd.
Povprečni promet
7,18 mio.
Promet
3,96 mio.
52-tedenski najvišji tečaj
28,24 $
52-tedenski najnižji tečaj
7,95 $
Čisti dobiček na delnico
−3,53 $
Beta
1,92
Št. izdanih delnic
139,72 mio.
Št. zaposlenih
377
Odpri
12,66 $
Visoka
13,14 $
Nizka
12,19 $
Tržna kapitalizacija
1,70 mrd.
Povprečni promet
7,18 mio.
Promet
3,96 mio.
52-tedenski najvišji tečaj
28,24 $
52-tedenski najnižji tečaj
7,95 $
Čisti dobiček na delnico
−3,53 $
Beta
1,92
Št. izdanih delnic
139,72 mio.
Št. zaposlenih
377
Obeti analitikov
Ocene analitikov
Na podlagi toliko analitikov: 18, ki so v zadnjih 3 mesecih ocenili delnice podjetja NTLA
Nakup
Nakup
8
Zadržanje
8
Prodaja
2
12-mesečna napoved
Na podlagi toliko analitikov z Wall Streeta: 18, ki so v zadnjih 3 mesecih podali ciljne cene za NTLA.
Najvišje
Trenutna 12,20 $
49,00 $ (+301,64%)
Povprečna
21,06 $ (+72,62%)
Najnižje
8,00 $ (−34,43%)
Novice
Iz virov v spletu
Stock Titan
·
pred 2 urama
Intellia Therapeutics (NTLA) director receives 9,200 RSUs and 13,300 stock options
Stock Titan
·
pred 2 urama
Intellia (NTLA) director Muna Bhanji granted 9,200 RSUs and 13,300 options
TipRanks
·
pred 3 urami
Intellia Shareholders Back Board, Executive Pay and Auditor
Yahoo Finance Singapore
·
pred 9 urami
Intellia Therapeutics (NTLA) Down 7.9% Since Last Earnings Report: Can It Rebound?
Profil
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.
The CRISPR gene editing system was originally invented by Jennifer Doudna, one of Intellia's scientific founders, and Virginijus Šikšnys. The company has entered into a number of different research and development collaborations with leading and emerging biotechnology companies including Novartis, Regeneron, Avencell, SparingVision, Kyverna, and ONK Therapeutics.
Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies. Wikipedia
Vizitka: Intellia Therapeutics Inc
Generalni direktorJohn Leonard
Št. zaposlenih377
Ustanovljeno2014
SedežCambridge, Massachusetts, Združene države Amerike
Sektor-
Spletno mestointelliatx.com
Vsebina z UI lahko vsebuje napake. Več o tem